Invention Grant
- Patent Title: Engineered monomeric antibody fragments
-
Application No.: US14650188Application Date: 2013-11-25
-
Publication No.: US10233229B2Publication Date: 2019-03-19
- Inventor: Tetsuya Ishino , Weili Duan , Ronald William Kriz
- Applicant: Pfizer Inc.
- Applicant Address: US NY New York
- Assignee: Pfizer Inc.
- Current Assignee: Pfizer Inc.
- Current Assignee Address: US NY New York
- International Application: PCT/IB2013/060384 WO 20131125
- International Announcement: WO2014/087299 WO 20140612
- Main IPC: C07K1/00
- IPC: C07K1/00 ; C07K16/00 ; C12P21/08 ; C07H21/04 ; C12P21/06 ; C12P21/04 ; C12N5/00

Abstract:
The present invention relates to monomeric polypeptides comprising an engineered monomeric antibody fragment (e.g., monomeric Fc-containing polypeptides) wherein the monomeric Fc comprises one or more engineered N-linked glycosylation sites in the CH3-CH3 dimerization interface. Methods for producing such engineered monomeric antibody fragments and their use in diagnostics and therapeutics are also provided.
Public/Granted literature
- US20150322135A1 ENGINEERED MONOMERIC ANTIBODY FRAGMENTS Public/Granted day:2015-11-12
Information query